Nov 28, 2023 / 06:20PM GMT
Umer Raffat - Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research
Thank you all for being here. Pleasure to have Gilead management here. There's a lot of topics to go through, including some of the FDA updates today, Andy, and I realize it's very early into the update. But maybe let me turn it over to you to kick things off.
Andrew D. Dickinson - Gilead Sciences, Inc. - Executive VP & CFO
Yes. Great. Thank you. First of all, thank you for having us. It's great to be here. It's great to do a conference in November in Miami. So thank you for that. And I appreciate everyone and spending time with us.
The -- maybe just quickly to kick it off. I mean, 2023 has been a great year for Gilead. You see the continued strength in our base business, the HIV business has performed extraordinarily well. The oncology business, which is both the Kite business and Trodelvy continue to grow. And it's just the beginning from our perspective.
I'd say the other thing that we focus investors on is we've been
Gilead Sciences Inc at Evercore ISI HealthCONx Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers